FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280493379> ?p ?o ?g. }

• W4280493379 endingPage "e004839" @default.
• W4280493379 startingPage "e004839" @default.
• W4280493379 abstract "Background Basal cell carcinoma (BCC) is the most common malignancy worldwide, yet the management of patients with advanced or metastatic disease is challenging, with limited treatment options. Recently, programmed death receptor 1 (PD-1) inhibition has demonstrated activity in BCC after prior Hedgehog inhibitor treatment. Methods We conducted a multicenter, retrospective analysis of BCC patients treated with PD-1 inhibitor therapy. We examined the efficacy and safety of PD-1 therapy, as well as clinical and pathological variables in association with outcomes. Progression-free survival (PFS), overall survival (OS) and duration of response (DOR) were calculated using Kaplan-Meier methodology. Toxicity was graded per Common Terminology Criteria for Adverse Events V.5.0. Results A total of 29 patients with BCC who were treated with PD-1 inhibition were included for analysis, including 20 (69.0%) with locally advanced and 9 (31.0%) with metastatic disease. The objective response rate was 31.0%, with five partial responses (17.2%), and four complete responses (13.8%). Nine patients had stable disease (31.0%), with a disease control rate of 62.1%. The median DOR was not reached. Median PFS was 12.2 months (95% CI 0.0 to 27.4). Median OS was 32.4 months (95% CI 18.1 to 46.7). Two patients (6.9%) developed grade 3 or higher toxicity, while four patients (13.8%) discontinued PD-1 inhibition because of toxicity. Higher platelets (p=0.022) and any grade toxicity (p=0.024) were significantly associated with disease control rate. Conclusions The clinical efficacy of PD-1 inhibition among patients with advanced or metastatic BCC in this real-world cohort were comparable to published trial data. Further investigation of PD-1 inhibition is needed to define its optimal role for patients with this disease." @default.
• W4280493379 created "2022-05-22" @default.
• W4280493379 creator A5001155783 @default.
• W4280493379 creator A5004649846 @default.
• W4280493379 creator A5007225202 @default.
• W4280493379 creator A5013046699 @default.
• W4280493379 creator A5014633686 @default.
• W4280493379 creator A5017296124 @default.
• W4280493379 creator A5026672076 @default.
• W4280493379 creator A5034786338 @default.
• W4280493379 creator A5035539932 @default.
• W4280493379 creator A5044045808 @default.
• W4280493379 creator A5044615683 @default.
• W4280493379 creator A5057459468 @default.
• W4280493379 creator A5057591852 @default.
• W4280493379 creator A5059210491 @default.
• W4280493379 creator A5061037221 @default.
• W4280493379 creator A5063474935 @default.
• W4280493379 creator A5076099967 @default.
• W4280493379 creator A5079826077 @default.
• W4280493379 date "2022-05-01" @default.
• W4280493379 modified "2023-10-16" @default.
• W4280493379 title "Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma" @default.
• W4280493379 cites W1557897376 @default.
• W4280493379 cites W1926140754 @default.
• W4280493379 cites W1970915933 @default.
• W4280493379 cites W1973774951 @default.
• W4280493379 cites W1995143994 @default.
• W4280493379 cites W1996800159 @default.
• W4280493379 cites W2002185973 @default.
• W4280493379 cites W2009147696 @default.
• W4280493379 cites W2011342967 @default.
• W4280493379 cites W2028192144 @default.
• W4280493379 cites W2033174520 @default.
• W4280493379 cites W2040600853 @default.
• W4280493379 cites W2056851027 @default.
• W4280493379 cites W2064928307 @default.
• W4280493379 cites W2087020583 @default.
• W4280493379 cites W2091113670 @default.
• W4280493379 cites W2097641710 @default.
• W4280493379 cites W2110135410 @default.
• W4280493379 cites W2112121482 @default.
• W4280493379 cites W2122406360 @default.
• W4280493379 cites W2128035403 @default.
• W4280493379 cites W2137271428 @default.
• W4280493379 cites W2139396899 @default.
• W4280493379 cites W2141183705 @default.
• W4280493379 cites W2152897456 @default.
• W4280493379 cites W2161540365 @default.
• W4280493379 cites W2167106546 @default.
• W4280493379 cites W2290862131 @default.
• W4280493379 cites W2293178613 @default.
• W4280493379 cites W2334577496 @default.
• W4280493379 cites W2339890238 @default.
• W4280493379 cites W2510686645 @default.
• W4280493379 cites W2560367415 @default.
• W4280493379 cites W2572174216 @default.
• W4280493379 cites W2587429794 @default.
• W4280493379 cites W2594507808 @default.
• W4280493379 cites W2747660904 @default.
• W4280493379 cites W2767119969 @default.
• W4280493379 cites W2779503684 @default.
• W4280493379 cites W2805968856 @default.
• W4280493379 cites W2888104081 @default.
• W4280493379 cites W2891965082 @default.
• W4280493379 cites W2958388343 @default.
• W4280493379 cites W2963476376 @default.
• W4280493379 cites W3010228464 @default.
• W4280493379 cites W3043022164 @default.
• W4280493379 cites W3043252982 @default.
• W4280493379 cites W3104819140 @default.
• W4280493379 cites W3155044719 @default.
• W4280493379 cites W3159164282 @default.
• W4280493379 cites W3160231856 @default.
• W4280493379 cites W3161927142 @default.
• W4280493379 cites W3193495508 @default.
• W4280493379 cites W3206586284 @default.
• W4280493379 cites W3209623215 @default.
• W4280493379 cites W4235732203 @default.
• W4280493379 cites W4237354326 @default.
• W4280493379 cites W4323284054 @default.
• W4280493379 doi "https://doi.org/10.1136/jitc-2022-004839" @default.
• W4280493379 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35545318" @default.
• W4280493379 hasPublicationYear "2022" @default.
• W4280493379 type Work @default.
• W4280493379 citedByCount "2" @default.
• W4280493379 countsByYear W42804933792022 @default.
• W4280493379 countsByYear W42804933792023 @default.
• W4280493379 crossrefType "journal-article" @default.
• W4280493379 hasAuthorship W4280493379A5001155783 @default.
• W4280493379 hasAuthorship W4280493379A5004649846 @default.
• W4280493379 hasAuthorship W4280493379A5007225202 @default.
• W4280493379 hasAuthorship W4280493379A5013046699 @default.
• W4280493379 hasAuthorship W4280493379A5014633686 @default.
• W4280493379 hasAuthorship W4280493379A5017296124 @default.
• W4280493379 hasAuthorship W4280493379A5026672076 @default.
• W4280493379 hasAuthorship W4280493379A5034786338 @default.
• W4280493379 hasAuthorship W4280493379A5035539932 @default.

• next